Lipid-lowering treatment in peripheral artery disease

The present narrative review discusses the use of statins and other lipid-lowering drugs such as ezetimibe, fibrates, niacin, anacetrapib and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in PAD patients in terms of both CV and limb outcomes. The clinical implications of hypolipidemic drug therapy in special patient populations including those with metabolic syndrome, non-alcoholic fatty liver disease, chronic kidney disease and type 2 diabetes mellitus, which may frequently co-exist with PAD, are also considered.